Nucelion Therapeutics is a cell and gene therapy contract research, development and manufacturing organisation (CRDMO) headquartered in Genome Valley, Hyderabad, India. The company provides a range of scientific, operational and manufacturing services to support the development and production of complex biological therapies. Its infrastructure integrates discovery-stage development, process optimisation and Good Manufacturing Practice (GMP) manufacturing under one roof, with facilities designed to meet global regulatory standards. Nucelion’s approach combines scientific precision with operational discipline to help innovators progress from early research through to clinical impact.

Key products and services

• End-to-end contract research, development and manufacturing (CRDMO) services for cell and gene therapies, including viral vectors (AAV, lentivirus) and cell therapies such as CAR-T, NK and iPSC-derived therapeutics.
• GMP suites and quality control laboratories supporting process development, scale-up and commercial manufacturing.
• Analytical services integrated with process and programme management to support product development through regulatory submissions.
• Capacity for multiple campaigns, including AAV, LVV, CAR-T and plasmid manufacturing, with phase-appropriate documentation and validation.

Nucelion Therapeutics operates as a wholly owned subsidiary of Bharat Biotech, reflecting the latter’s strategic expansion into advanced therapeutics manufacturing. The company’s facilities and services are designed to support global life-science innovators with scalable solutions that align with international regulatory requirements. By providing integrated CRDMO capabilities, Nucelion aims to accelerate the development and delivery of next-generation cell and gene therapies to patients worldwide.